California-based single-cell deoxyribonucleic acid (DNA) analysis and precision genomics company Mission Bio, Inc. has scored $30 million in Series B funding round.
Mission Bio, Inc plans to use the funds to scale its single-cell DNA technology, the Tapestri Platform, by extending the market for blood cancer research, while also widening its scope to clustered regularly interspaced short palindromic repeats applications and expanding into global markets.
Investors in the round included Agilent Technologies, Cota Capital, LAM Capital, and Mayfield.
Mission Bio has secured over $50 million in total funding.